Table 5. Effect of SGLT2 inhibitor on primary endpoints by background therapy.
| Trial name | DAPA-HF7,83 | EMPEROR-reduced8,84 | ||
| Drug name | Dapagliflozin | Empagliflozin | ||
| HR (95% CI) | p for interaction | HR (95% CI) | p for interaction | |
| Overall effect | 0.74 (0.65-0.85) | 0.75 (0.65-0.86) | ||
| ARNI | 1.00 | NR | ||
| Yes | 0.75 (0.50-1.13) | 0.64 (0.45-0.89) | ||
| No | 0.74 (0.65-0.86) | 0.77 (0.66-0.90) | ||
| ACEI/ARB target dose | 0.21 | 0.18 | ||
| < 50% | 0.78 (0.65-0.94) | 0.85 (0.69-1.06) | ||
| ≥ 50% | 0.64 (0.50-0.82) | 0.67 (0.52-0.88) | ||
| Beta-blocker target dose | 0.76 | 0.15 | ||
| < 50% | 0.71 (0.59-0.86) | 0.66 (0.54-0.80) | ||
| ≥ 50% | 0.74 (0.60-0.90) | 0.81 (0.66-1.00) | ||
| MRA target dose | 0.82 | 0.96 | ||
| < 50% | 0.71 (0.45-1.12) | 0.77 (0.22-2.63) | ||
| ≥ 50% | 0.74 (0.63-0.88) | 0.75 (0.63-0.88) | ||
| ACEI/ARB ≥ 50% target dose + beta-blocker ≥ 50% target dose | 0.40 | 0.96 | ||
| Yes | 0.66 (0.48-0.91) | 0.74 (0.54-1.03) | ||
| No | 0.77 (0.66-0.89) | 0.75 (0.64-0.87) | ||
| ACEI, ARB, or ARNI + beta-blocker (all at any dose) | NR | 0.64 | ||
| Yes | NR | 0.68 (0.60-0.77) | ||
| No | NR | 0.73 (0.56-0.94) | ||
| ARNI + beta-blocker + MRA (all at any dose) | 0.86 | 0.15 | ||
| Yes | 0.70 (0.41-1.19) | 0.55 (0.35-0.86) | ||
| No | 0.74 (0.65-0.85) | 0.77 (0.67-0.89) | ||
| ACEI/ARB + beta-blocker + MRA (all ≥ 50% target dose) | 0.65 | 0.71 | ||
| Yes | 0.70 (0.48-1.01) | 0.80 (0.55-1.17) | ||
| No | 0.75 (0.65-0.87) | 0.74 (0.64-0.86) | ||
| ACEI, ARB, or ARNI + beta-blocker + MRA (all at any dose) | NR | 0.73 | ||
| Yes | NR | 0.68 (0.58-0.79) | ||
| No | NR | 0.70 (0.59-0.84) |
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; CI, confidence interval; HF, heart failure; HR, hazard ratio; MRA, mineralocorticoid receptor antagonist; NR, not reported; SGLT2i, sodium-glucose co-transporter 2 inhibitor.